Ozempic denials: what the review data shows
Independent reviewers have decided 139 published cases where an insurer denied Ozempic — and they overturned the insurer 65.5% of the time. A denial for Ozempic is a starting position, not a final answer.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 45 | 73.3% |
| Type 2 Diabetes | 22 | 68.2% |
| Type 1 Diabetes | 15 | 80% |
| Diabetes | 13 | 61.5% |
| Type 2 Diabetes Mellitus | 12 | 83.3% |
| Prediabetes | 12 | 25% |
Why plans deny Ozempic — and how appeals win
Ozempic (semaglutide) is FDA-approved for: type 2 diabetes. Denials that treat an on-label prescription as unproven or cosmetic are the ones reviewers reverse most readily.
Indication mismatch
Ozempic is approved for type 2 diabetes; the weight-management version of semaglutide is Wegovy. Requests coded to obesity or prediabetes rather than type 2 diabetes are the classic Ozempic denial — and the published outcomes show reviewers back plans on true off-label weight-loss requests far more often than on diabetes requests.
Step therapy before GLP-1 coverage
Metformin-first requirements dominate. A denial for “step therapy not met” is usually a documentation gap — the trials happened but never made it into the prior-auth request.
Supply-driven quantity and refill denials
Dose titration and shortage-era substitutions produce quantity-limit and refill denials that have nothing to do with medical necessity. These are process denials and get fixed by exception requests more than by argument.
Plans must maintain an exception process for their step-therapy rules. Documented failure or intolerance of metformin or other preferred agents — stated by the prescriber with specifics — is the standard winning ground.
What winning Ozempic appeals argue
- Anchor the appeal to the type 2 diabetes diagnosis: codes, A1C trend, current regimen, and the clinical goal Ozempic serves.
- List every preferred agent already tried, with outcomes — that single paragraph defeats most step-therapy denials.
- If the real goal is weight management without diabetes, the on-label semaglutide product is Wegovy; appeals argue far better on-label.
- For patients stable on Ozempic facing a formulary change: continuity-of-care rules in many states and plans protect ongoing therapy — invoke them.
The published record backs the effort: 139 external-review decisions on Ozempic denials, 65.5% overturned. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Ozempicwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY